Relapsing MS - CONCERTO
Initial results from the CONCERTO trial were announced in May 2017. Laquinimod did not slow disability progression compared with placebo and the trial has now been discontinued.
The trial aimed to test the benefits of two doses of laquinimod (0.6mg and 1.2mg) on disability progression in around 1,800 people with relapsing MS. The higher dose was removed due to safety concerns relating to cardiovascular side effects.
Primary progressive MS - ARPEGGIO
This phase 2 study aimed to test the benefits of 48 weeks of two doses of laquinimod (0.6mg and 1.5mg) compared with placebo in 375 people with primary progressive MS. Due to safety concerns the higher dose of laquinimod was removed.
The trial finished in 2017 and we expect results early in 2018. Researchers are looking for brain volume changes, progression of disability and new lesions measured by MRI to show whether the drug is effective .